康辰药业：KC1086项目获得临床试验受理通知书

Core Viewpoint - Kangchen Pharmaceutical (603590) has received approval from the National Medical Products Administration for the clinical trial application of its innovative chemical drug KC1086, aimed at treating advanced recurrent or metastatic solid tumors [1] Group 1 - KC1086 is a small molecule inhibitor of Lysine Acetyltransferase 6 (KAT6), developed entirely by the company [1] - The drug is classified as a Class 1 innovative chemical drug, with specifications of 1mg and 4mg [1] - This marks the first clinical trial application for KC1086, indicating a significant milestone in the drug's development process [1]